 Teri Schreiner
Concepts (229)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Multiple Sclerosis | 31 | 2023 | 429 | 5.470 |
Why?
| | Neuromyelitis Optica | 4 | 2023 | 127 | 1.210 |
Why?
| | Myelitis | 4 | 2020 | 99 | 0.930 |
Why?
| | Multiple Sclerosis, Relapsing-Remitting | 3 | 2019 | 70 | 0.840 |
Why?
| | Cranial Nerve Diseases | 3 | 2017 | 42 | 0.790 |
Why?
| | Immunosuppressive Agents | 5 | 2023 | 706 | 0.760 |
Why?
| | Cerebral Veins | 1 | 2021 | 16 | 0.730 |
Why?
| | Microvessels | 1 | 2021 | 79 | 0.690 |
Why?
| | Central Nervous System Diseases | 1 | 2021 | 68 | 0.690 |
Why?
| | Cerebral Hemorrhage | 1 | 2021 | 108 | 0.690 |
Why?
| | Nervous System Diseases | 4 | 2019 | 261 | 0.660 |
Why?
| | Venous Thrombosis | 1 | 2021 | 165 | 0.640 |
Why?
| | Sarcoidosis | 1 | 2021 | 151 | 0.630 |
Why?
| | Enterovirus Infections | 5 | 2020 | 171 | 0.580 |
Why?
| | Immunologic Factors | 2 | 2019 | 230 | 0.550 |
Why?
| | Myelin-Oligodendrocyte Glycoprotein | 3 | 2023 | 48 | 0.540 |
Why?
| | Movement Disorders | 1 | 2017 | 53 | 0.540 |
Why?
| | Muscular Diseases | 1 | 2017 | 110 | 0.530 |
Why?
| | Child | 32 | 2023 | 20963 | 0.520 |
Why?
| | Dimethyl Fumarate | 1 | 2016 | 11 | 0.520 |
Why?
| | Adolescent | 28 | 2023 | 20355 | 0.510 |
Why?
| | Recurrence | 5 | 2023 | 1016 | 0.470 |
Why?
| | Rituximab | 3 | 2022 | 161 | 0.460 |
Why?
| | Cognitive Dysfunction | 2 | 2022 | 329 | 0.430 |
Why?
| | HLA-DRB1 Chains | 5 | 2023 | 107 | 0.420 |
Why?
| | Gene-Environment Interaction | 3 | 2023 | 185 | 0.410 |
Why?
| | Demyelinating Diseases | 3 | 2023 | 82 | 0.400 |
Why?
| | Genetic Predisposition to Disease | 6 | 2023 | 2272 | 0.380 |
Why?
| | Magnetic Resonance Imaging | 7 | 2023 | 3351 | 0.370 |
Why?
| | Epstein-Barr Virus Infections | 2 | 2022 | 93 | 0.360 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2023 | 751 | 0.350 |
Why?
| | Paralysis | 3 | 2016 | 72 | 0.350 |
Why?
| | Male | 36 | 2023 | 63544 | 0.340 |
Why?
| | Humans | 52 | 2023 | 129706 | 0.330 |
Why?
| | Central Nervous System Viral Diseases | 2 | 2020 | 73 | 0.310 |
Why?
| | Autoantibodies | 4 | 2023 | 1463 | 0.300 |
Why?
| | Vaccines | 1 | 2014 | 406 | 0.300 |
Why?
| | Female | 33 | 2023 | 68562 | 0.300 |
Why?
| | Muscle Hypotonia | 2 | 2020 | 32 | 0.300 |
Why?
| | Neuromuscular Diseases | 2 | 2020 | 106 | 0.300 |
Why?
| | Aquaporin 4 | 3 | 2023 | 95 | 0.300 |
Why?
| | Muscle, Skeletal | 1 | 2017 | 1632 | 0.280 |
Why?
| | Fingolimod Hydrochloride | 1 | 2023 | 36 | 0.270 |
Why?
| | Sunlight | 1 | 2021 | 71 | 0.270 |
Why?
| | Cognition Disorders | 2 | 2022 | 496 | 0.270 |
Why?
| | Age of Onset | 6 | 2023 | 494 | 0.260 |
Why?
| | Case-Control Studies | 11 | 2023 | 3363 | 0.260 |
Why?
| | Adjuvants, Immunologic | 2 | 2020 | 224 | 0.260 |
Why?
| | Treatment Outcome | 4 | 2020 | 10299 | 0.240 |
Why?
| | Vaccination | 1 | 2014 | 1362 | 0.240 |
Why?
| | Neuropsychological Tests | 2 | 2022 | 996 | 0.230 |
Why?
| | Menarche | | | 58 | NaN |
Why?
| | Vitamin D | 2 | 2019 | 384 | 0.230 |
Why?
| | Disease Progression | 3 | 2023 | 2612 | 0.230 |
Why?
| | Enterovirus D, Human | 2 | 2016 | 82 | 0.220 |
Why?
| | Risk Factors | 11 | 2023 | 9832 | 0.210 |
Why?
| | Axons | | | 181 | NaN |
Why?
| | Environmental Exposure | 2 | 2018 | 479 | 0.210 |
Why?
| | Autoimmune Diseases of the Nervous System | 1 | 2023 | 23 | 0.210 |
Why?
| | Immunoglobulin G | 3 | 2022 | 842 | 0.190 |
Why?
| | Parents | 1 | 2017 | 1311 | 0.180 |
Why?
| | Lipids | | | 614 | NaN |
Why?
| | Follow-Up Studies | 4 | 2020 | 4939 | 0.180 |
Why?
| | Multiple Sclerosis, Chronic Progressive | 1 | 2020 | 26 | 0.170 |
Why?
| | Muscle Weakness | 1 | 2020 | 85 | 0.170 |
Why?
| | Clinical Trials as Topic | | | 1008 | NaN |
Why?
| | Retrospective Studies | 7 | 2023 | 14669 | 0.160 |
Why?
| | Glatiramer Acetate | 1 | 2019 | 18 | 0.160 |
Why?
| | Enterovirus | 1 | 2019 | 78 | 0.160 |
Why?
| | Child, Preschool | 8 | 2020 | 10565 | 0.160 |
Why?
| | Oxidoreductases | 1 | 2019 | 91 | 0.160 |
Why?
| | Education, Special | 1 | 2018 | 23 | 0.160 |
Why?
| | Disabled Persons | 1 | 2020 | 136 | 0.150 |
Why?
| | Polymorphism, Single Nucleotide | 4 | 2019 | 2071 | 0.150 |
Why?
| | Disability Evaluation | 2 | 2020 | 291 | 0.150 |
Why?
| | Research Design | | | 1048 | NaN |
Why?
| | Fluoxetine | 1 | 2018 | 53 | 0.150 |
Why?
| | Disease Susceptibility | 2 | 2017 | 339 | 0.150 |
Why?
| | Electromyography | 2 | 2017 | 380 | 0.150 |
Why?
| | Autoimmune Diseases | 1 | 2021 | 422 | 0.140 |
Why?
| | Cohort Studies | 3 | 2020 | 5410 | 0.140 |
Why?
| | B-Lymphocytes | 1 | 2023 | 816 | 0.140 |
Why?
| | Neural Conduction | 1 | 2017 | 82 | 0.140 |
Why?
| | Atrophy | 1 | 2017 | 165 | 0.140 |
Why?
| | United States | 9 | 2021 | 14078 | 0.130 |
Why?
| | Young Adult | 7 | 2020 | 12363 | 0.130 |
Why?
| | Recovery of Function | 1 | 2020 | 643 | 0.130 |
Why?
| | Adult | 12 | 2023 | 35596 | 0.130 |
Why?
| | Communicable Diseases | 1 | 2018 | 143 | 0.130 |
Why?
| | Attitude | 1 | 2017 | 248 | 0.130 |
Why?
| | Developmental Disabilities | 1 | 2018 | 255 | 0.130 |
Why?
| | Sodium Chloride, Dietary | 1 | 2016 | 36 | 0.130 |
Why?
| | Dietary Fats | 1 | 2017 | 303 | 0.120 |
Why?
| | Encephalomyelitis, Acute Disseminated | 1 | 2015 | 11 | 0.120 |
Why?
| | Transgender Persons | 2 | 2016 | 174 | 0.120 |
Why?
| | Perception | 1 | 2017 | 339 | 0.120 |
Why?
| | Gonadal Steroid Hormones | 1 | 2016 | 134 | 0.120 |
Why?
| | Marijuana Abuse | 1 | 2017 | 230 | 0.120 |
Why?
| | Colorado | 4 | 2019 | 4471 | 0.120 |
Why?
| | Nuclear Proteins | 1 | 2019 | 644 | 0.120 |
Why?
| | Paraplegia | 1 | 2014 | 58 | 0.110 |
Why?
| | Bone Remodeling | 1 | 2015 | 71 | 0.110 |
Why?
| | Marijuana Smoking | 1 | 2017 | 241 | 0.110 |
Why?
| | Motor Neurons | 1 | 2016 | 236 | 0.110 |
Why?
| | Patient Reported Outcome Measures | 1 | 2017 | 359 | 0.110 |
Why?
| | Bacterial Vaccines | 1 | 2014 | 65 | 0.110 |
Why?
| | Administration, Oral | 1 | 2016 | 790 | 0.110 |
Why?
| | CD40 Antigens | 1 | 2014 | 87 | 0.110 |
Why?
| | Prospective Studies | 5 | 2020 | 7131 | 0.110 |
Why?
| | T-Lymphocytes, Helper-Inducer | 1 | 2014 | 137 | 0.110 |
Why?
| | Hypersensitivity | 1 | 2017 | 277 | 0.110 |
Why?
| | Antiviral Agents | 1 | 2018 | 709 | 0.100 |
Why?
| | Viral Vaccines | 1 | 2014 | 94 | 0.100 |
Why?
| | MicroRNAs | 1 | 2019 | 671 | 0.100 |
Why?
| | Neuroimaging | 1 | 2014 | 273 | 0.100 |
Why?
| | Longitudinal Studies | 1 | 2020 | 2670 | 0.100 |
Why?
| | Severity of Illness Index | 1 | 2020 | 2783 | 0.100 |
Why?
| | Medication Adherence | 1 | 2017 | 576 | 0.100 |
Why?
| | T-Lymphocyte Subsets | 1 | 2014 | 413 | 0.090 |
Why?
| | Herpesvirus 4, Human | 2 | 2022 | 153 | 0.090 |
Why?
| | Testosterone | 1 | 2015 | 382 | 0.090 |
Why?
| | Bone Density | 1 | 2015 | 470 | 0.090 |
Why?
| | Patient Outcome Assessment | 2 | 2023 | 129 | 0.090 |
Why?
| | Body Composition | 1 | 2015 | 657 | 0.090 |
Why?
| | Transcription Factors | 1 | 2019 | 1636 | 0.090 |
Why?
| | Feeding Behavior | 1 | 2016 | 624 | 0.090 |
Why?
| | Ultraviolet Rays | 2 | 2023 | 380 | 0.080 |
Why?
| | Death, Sudden | 1 | 2009 | 25 | 0.080 |
Why?
| | Disease Outbreaks | 3 | 2019 | 333 | 0.080 |
Why?
| | Diet | 1 | 2017 | 1214 | 0.080 |
Why?
| | Influenza A Virus, H1N1 Subtype | 1 | 2010 | 147 | 0.080 |
Why?
| | Vena Cava, Inferior | 1 | 2009 | 68 | 0.080 |
Why?
| | Constriction, Pathologic | 1 | 2009 | 230 | 0.080 |
Why?
| | Body Mass Index | 1 | 2017 | 2246 | 0.080 |
Why?
| | Neoplasms, Germ Cell and Embryonal | 1 | 2009 | 66 | 0.080 |
Why?
| | Testicular Neoplasms | 1 | 2009 | 101 | 0.070 |
Why?
| | Alleles | 2 | 2023 | 849 | 0.070 |
Why?
| | Biomarkers | 3 | 2019 | 3893 | 0.070 |
Why?
| | Genotype | 2 | 2023 | 1836 | 0.070 |
Why?
| | Sweden | 2 | 2017 | 93 | 0.070 |
Why?
| | Cross-Sectional Studies | 2 | 2023 | 5050 | 0.070 |
Why?
| | Referral and Consultation | 1 | 2017 | 731 | 0.060 |
Why?
| | Surveys and Questionnaires | 2 | 2023 | 5396 | 0.060 |
Why?
| | Middle Aged | 6 | 2020 | 31103 | 0.060 |
Why?
| | Risk | 2 | 2019 | 871 | 0.060 |
Why?
| | Demyelinating Autoimmune Diseases, CNS | | | 3 | NaN |
Why?
| | Haplotypes | 2 | 2019 | 476 | 0.060 |
Why?
| | Phosphatidylethanolamines | | | 74 | NaN |
Why?
| | Neurofilament Proteins | | | 45 | NaN |
Why?
| | Influenza, Human | 1 | 2010 | 610 | 0.060 |
Why?
| | Phosphatidylcholines | | | 146 | NaN |
Why?
| | Brain | 2 | 2019 | 2596 | 0.050 |
Why?
| | Cognition | 2 | 2022 | 1098 | 0.050 |
Why?
| | Memory and Learning Tests | 1 | 2022 | 1 | 0.050 |
Why?
| | Infant | 4 | 2020 | 9097 | 0.050 |
Why?
| | Azathioprine | 1 | 2022 | 51 | 0.050 |
Why?
| | Logistic Models | 2 | 2018 | 1980 | 0.050 |
Why?
| | Demography | 1 | 2023 | 282 | 0.050 |
Why?
| | Genome-Wide Association Study | 2 | 2019 | 1334 | 0.050 |
Why?
| | Pandemics | 1 | 2010 | 1526 | 0.050 |
Why?
| | Infusions, Intravenous | 1 | 2023 | 399 | 0.050 |
Why?
| | Immunoglobulins, Intravenous | 1 | 2022 | 135 | 0.050 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 1 | 2023 | 229 | 0.050 |
Why?
| | Proportional Hazards Models | | | 1227 | NaN |
Why?
| | HLA Antigens | 1 | 2023 | 236 | 0.050 |
Why?
| | Social Determinants of Health | | | 218 | NaN |
Why?
| | Hospitalization | 1 | 2010 | 2091 | 0.040 |
Why?
| | Antigens, CD20 | 1 | 2020 | 28 | 0.040 |
Why?
| | Dose-Response Relationship, Drug | | | 1969 | NaN |
Why?
| | HIV Infections | 1 | 2015 | 2744 | 0.040 |
Why?
| | Prevalence | 2 | 2017 | 2557 | 0.040 |
Why?
| | Stiff-Person Syndrome | 1 | 2019 | 12 | 0.040 |
Why?
| | HLA-A3 Antigen | 1 | 2019 | 6 | 0.040 |
Why?
| | HLA-B7 Antigen | 1 | 2019 | 7 | 0.040 |
Why?
| | Enzyme Inhibitors | 1 | 2022 | 828 | 0.040 |
Why?
| | Maintenance Chemotherapy | 1 | 2019 | 23 | 0.040 |
Why?
| | Interleukin-6 | 1 | 2023 | 715 | 0.040 |
Why?
| | Glutamate Decarboxylase | 1 | 2019 | 165 | 0.040 |
Why?
| | Mathematical Concepts | 1 | 2018 | 25 | 0.040 |
Why?
| | Sex Factors | | | 1952 | NaN |
Why?
| | Propensity Score | 1 | 2020 | 263 | 0.040 |
Why?
| | Induction Chemotherapy | 1 | 2019 | 70 | 0.040 |
Why?
| | Syndrome | 1 | 2019 | 343 | 0.040 |
Why?
| | Aged | 4 | 2019 | 22113 | 0.040 |
Why?
| | Central Nervous System | 1 | 2020 | 255 | 0.040 |
Why?
| | Biomedical Research | | | 656 | NaN |
Why?
| | Global Health | 1 | 2020 | 333 | 0.040 |
Why?
| | Geography, Medical | 1 | 2017 | 11 | 0.040 |
Why?
| | Habits | 1 | 2017 | 43 | 0.040 |
Why?
| | California | 1 | 2019 | 403 | 0.040 |
Why?
| | Knowledge | 1 | 2017 | 52 | 0.040 |
Why?
| | Water Quality | 1 | 2017 | 31 | 0.040 |
Why?
| | Reading | 1 | 2018 | 150 | 0.040 |
Why?
| | Diet Surveys | 1 | 2017 | 92 | 0.030 |
Why?
| | Mendelian Randomization Analysis | 1 | 2017 | 50 | 0.030 |
Why?
| | Gene Regulatory Networks | 1 | 2019 | 278 | 0.030 |
Why?
| | Family | 1 | 2021 | 655 | 0.030 |
Why?
| | Vegetables | 1 | 2017 | 146 | 0.030 |
Why?
| | North America | 1 | 2017 | 293 | 0.030 |
Why?
| | Registries | | | 2008 | NaN |
Why?
| | Binding Sites | 1 | 2019 | 1238 | 0.030 |
Why?
| | Gender Identity | 1 | 2016 | 115 | 0.030 |
Why?
| | Regression Analysis | 1 | 2017 | 992 | 0.030 |
Why?
| | Odds Ratio | 1 | 2017 | 1025 | 0.030 |
Why?
| | Genetic Testing | 1 | 2017 | 425 | 0.030 |
Why?
| | Air Pollution | 1 | 2017 | 223 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2018 | 1507 | 0.030 |
Why?
| | Brain Stem | 1 | 2014 | 95 | 0.030 |
Why?
| | Parkinson Disease | 1 | 2019 | 408 | 0.030 |
Why?
| | Double-Blind Method | 1 | 2019 | 1871 | 0.030 |
Why?
| | Self Efficacy | 1 | 2017 | 385 | 0.030 |
Why?
| | Cluster Analysis | 1 | 2014 | 482 | 0.030 |
Why?
| | HLA-DR Antigens | 1 | 2014 | 226 | 0.030 |
Why?
| | Cell Separation | 1 | 2014 | 313 | 0.030 |
Why?
| | Self Report | 1 | 2017 | 798 | 0.020 |
Why?
| | Gene Expression Profiling | 1 | 2019 | 1696 | 0.020 |
Why?
| | Muscle Strength | 1 | 2015 | 309 | 0.020 |
Why?
| | Animals | 1 | 2014 | 34733 | 0.020 |
Why?
| | Acute Disease | 1 | 2014 | 984 | 0.020 |
Why?
| | Flow Cytometry | 1 | 2014 | 1151 | 0.020 |
Why?
| | Time Factors | 1 | 2020 | 6593 | 0.020 |
Why?
| | Autopsy | 1 | 2009 | 92 | 0.020 |
Why?
| | Autoimmunity | 1 | 2014 | 869 | 0.020 |
Why?
| | Neoplasm Metastasis | 1 | 2009 | 610 | 0.020 |
Why?
| | Vascular Diseases | 1 | 2009 | 242 | 0.020 |
Why?
| | Signal Transduction | 1 | 2019 | 4863 | 0.020 |
Why?
| | Phenotype | 1 | 2014 | 3063 | 0.020 |
Why?
| | Asthma | 1 | 2017 | 2257 | 0.010 |
Why?
| | Age Factors | 1 | 2010 | 3145 | 0.010 |
Why?
|
|
Schreiner's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|